TickerFacts.

A business in context

OVID research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001628280-26-056498

  2. 8-K · Current report

    Report date 2026-08-11 · 0001628280-26-056497 · Items 9.01

  3. 4 · Ownership change

    Report date 2026-07-06 · 0001779359-26-000004

  4. 8-K · Current report

    Report date 2026-07-05 · 0001628280-26-047584 · Items 5.02

  5. 4 · Ownership change

    Report date 2026-06-15 · 0002138163-26-000005

  6. 8-K · Current report

    Report date 2026-06-11 · 0001628280-26-042396 · Items 5.07

  7. 8-K · Current report

    Report date 2026-05-29 · 0001628280-26-040038 · Items 5.02

  8. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001628280-26-033864

  9. 8-K · Current report

    Report date 2026-05-12 · 0001628280-26-033859 · Items 9.01

  10. DEF 14A · Proxy statement

    Report date 2025-12-31 · 0001628280-26-027621

  11. 8-K · Current report

    Report date 2026-04-17 · 0001628280-26-025926 · Items 8.01

  12. 4 · Ownership change

    Report date 2026-04-07 · 0001886431-26-000004

  13. 4 · Ownership change

    Report date 2026-04-07 · 0001368324-26-000004

  14. 4 · Ownership change

    Report date 2026-04-07 · 0001202098-26-000004

  15. 4 · Ownership change

    Report date 2026-03-23 · 0001256153-26-000004

  16. 10-K · Annual report

    Report date 2025-12-31 · 0001628280-26-019438

  17. 8-K · Current report

    Report date 2026-03-17 · 0001628280-26-019045 · Items 1.01,2.02,3.02,9.01

  18. 4 · Ownership change

    Report date 2026-02-23 · 0002036798-26-000004

  19. 4 · Ownership change

    Report date 2026-02-26 · 0001886431-26-000002

  20. 8-K · Current report

    Report date 2025-12-18 · 0001193125-25-323798 · Items 8.01,9.01

  21. 8-K · Current report

    Report date 2025-12-11 · 0001636651-25-000017 · Items 5.07

  22. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001636651-25-000012

  23. 8-K · Current report

    Report date 2025-11-12 · 0001636651-25-000011 · Items 2.02,5.02,9.01

  24. DEF 14A · Proxy statement

    Report date 2025-12-11 · 0001140361-25-040884

  25. 8-K · Current report

    Report date 2025-10-02 · 0001193125-25-230409 · Items 1.01,3.02,5.03,8.01,9.01

  26. 8-K · Current report

    Report date 2025-09-11 · 0001193125-25-204308 · Items 8.01

  27. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001628280-25-040008

  28. 8-K · Current report

    Report date 2025-08-13 · 0001628280-25-040007 · Items 9.01

  29. 8-K · Current report

    Report date 2025-07-10 · 0001628280-25-034733 · Items 5.07

  30. 8-K · Current report

    Report date 2025-06-25 · 0001628280-25-032959 · Items 8.01

  31. DEF 14A · Proxy statement

    Report date 2024-12-31 · 0001628280-25-027146

  32. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001628280-25-024913

  33. 8-K · Current report

    Report date 2025-05-13 · 0001628280-25-024911 · Items 2.02

  34. 8-K · Current report

    Report date 2025-05-01 · 0001193125-25-111633 · Items 5.08

  35. 10-K/A · Annual report

    Report date 2024-12-31 · 0001628280-25-021055

  36. 10-K · Annual report

    Report date 2024-12-31 · 0001628280-25-011844

  37. 8-K · Current report

    Report date 2025-03-10 · 0001628280-25-011839 · Items 2.02

  38. 8-K · Current report

    Report date 2025-03-01 · 0001193125-25-047174 · Items 5.02

  39. 8-K · Current report

    Report date 2025-02-10 · 0001193125-25-026192 · Items 3.01

  40. SC 13G/A · Ownership disclosure

    0000935836-24-000717

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 1 transaction rows1AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

1 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-07-06
2026-07-08
Carter Charles RossA · Grant / award
Acquired
Common Stock50000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001636651Ovid Therapeutics Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names

    Revenue in constant purchasing power

    USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

    Year endedReported USD revenueCPI-adjusted USD revenue
    2024-12-31$566.0K$607.9K
    2023-12-31$392.0K$433.4K
    2022-12-31$1.50M$1.73M
    2021-12-31$208.38M$259.07M
    2020-12-31$12.62M$16.43M

    Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

    Explore the CPI history ↗